<DOC>
	<DOCNO>NCT03100318</DOCNO>
	<brief_summary>FYU-981 Benzbromarone administrate hyperuricemia patient without gout 14 week compare efficacy safety drug method multicenter , randomize , double-blind , ascend dose regimen .</brief_summary>
	<brief_title>Benzbromarone-Controlled , Double-Blind , Comparative Study FYU-981 Hyperuricemia With Without Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Benzbromarone</mesh_term>
	<criteria>Hyperuricemic gout patient Serum urate level : &gt; = 7.0mg/dL patient history gout , &gt; = 8.0mg/dL patient hypertension , diabetes metabolic syndrome , &gt; = 9.0mg/dL Gouty arthritis within two week start study treatment Secondary hyperuricemia HbA1c : &gt; = 8.4 % Uric acidoverproduction type classification hyperuricemia History , clinically significant cardiac , hematologic hepatic disease Kidney calculi clinically significant urinary calculus Hepatic dysfuction , AST : &gt; =100 IU/L ALT : &gt; =100 IU/L preexamination eGFR : &lt; 30mL/min/1.73m^2 Systolic blood pressure : &gt; = 180 mmHg Diastolic blood pressure : &gt; = 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>